Anti-Casein Kinase 2 beta antibody [EP1995Y]

5 product images

• 

  Western blot - Anti-Casein Kinase 2 beta antibody [EP1995Y] (ab76025)

  All lanes: Western blot - Anti-Casein Kinase 2 beta antibody [EP1995Y] (ab76025) at 1/1000 dilution

  All lanes: K562 cell lysate at 10 µg

  Secondary

  All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution

  Predicted band size: 24 kDa

  Observed band size: 25 kDa

• 

  Immunocytochemistry/ Immunofluorescence - Anti-Casein Kinase 2 beta antibody [EP1995Y] (ab76025)

  Immunofluorescent staining of Casein Kinase 2 beta in HeLa cells using ab76025 at a 1/100 dilution.

• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Casein Kinase 2 beta antibody [EP1995Y] (ab76025)

  Immunohistochemical analysis of Casein Kinase 2 beta in paraffin embedded human ovary carcinoma tissue using ab76025 at a 1/100 dilution.
  

  Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

• 

  Flow Cytometry (Intracellular) - Anti-Casein Kinase 2 beta antibody [EP1995Y] (ab76025)

  Overlay histogram showing HeLa cells stained with ab76025 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab76025, 1/100 dilution) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1μg/1x10⁶ cells) used under the same conditions. Acquisition of >5,000 events was performed.

• 

  Image collected and cropped by CiteAb under a CC-BY license from the publication

  Western blot - Anti-Casein Kinase 2 beta antibody [EP1995Y] (ab76025)

  Casein Kinase 2 beta western blot using anti-Casein Kinase 2 beta antibody [EP1995Y] ab76025. Publication image and figure legend from Di Maira, G., Gentilini, A., et al., 2019, Oncogenesis, PubMed 31641101.

  
  

  ab76025 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab76025 please see the product overview.

  Expression and activity of CK2 in cholangiocarcinoma samples and CCA cells lines.a Expression of CK2 catalytic (CSNK2A1 and CSNK2A2) and regulatory (CSNK2B) subunits in human CCA tissues. CK2α, CK2α’ and CK2β mRNA expression were significantly increased in tumor lesions (T) (n = 104) compared to surrounding matched normal liver tissue (SL) (n = 60) using transcriptome data of CCA patients35. Statistical significance was determined by nonparametric Mann–Whitney test. Individual patient data are shown, and the thick horizontal line indicates the mean of the values. §, P < 0.001 vs. T. b Relative quantitation of gene expression of CK2α, CK2α’ and CK2β in cholangiocytes, HUCCT-1 and CCLP-1 cells. *p < 0.05 versus cholangiocytes. (c) Twenty µg (left panel) or 40 µg (right panel) of proteins from total cell lysate were analyzed by Western blot with the indicated antibodies. Tubulin was used as a loading control. d Activity of CK2 in cell lysates was measured using a CK2-specific peptide substrate. *p < 0.05 versus cholangiocytes